The Framingham risk score and heart disease in nonalcoholic fatty liver disease

Liver International

Volumn 32, Issue 6, 2012, Pages 945-950

  Treeprasertsuk, Sombat ^a,b   Leverage, Scott ^c   Adams, Leon A ^d   Lindor, Keith D ^a   St Sauver, Jennifer ^a   Angulo, Paul ^c  

^a MAYO CLINIC   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; FATTY LIVER; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SELECTION; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84861992004     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02753.x     Document Type: Article

References (24)

1. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010; 26: 202-8.
2. Adams LA, Lymp JF, StSauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
3. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
4. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
5. Soderberg C, Stal P, Askling J, et al. Decreased survival of subject with elevated liver function test during a 28-year follow up. Hepatology 2010; 51: 595-602.
6. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology 2006; 130: 1848-52.
7. Cheung O, Kapoor A, Puri P, et al. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007; 46: 1091-100.
8. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008; 43: 509-18.
9. Goessling W, Massaro JM, Vasan RS, et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135: 1935-44.
10. Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103: 2263-71.
11. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and γ-glutamyltransferase and mortality in the united states population. Gastroenterology 2009; 136: 477-85.
12. Elinav E, Ackerman Z, Maaravi Y, et al. Low alanine aminotransferase activity in older people is associated with greater long-term mortality. J Am Geriatr Soc 2006; 54: 1719-24.
13. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010; 52: 1156-61.
14. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.
15. Eichler K, Puhan MA, Steurer J, Bachmann LM. Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 2007;153:722-31, 731 e721-728.
16. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
17. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006; 43: 1145-51.
18. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. [see Comment]. Hepatology 2005; 42: 473-80.
19. Melton LJ. 3rd. History of the Rochester epidemiology project. Mayo Clin Proc 1996; 71: 266-74.
20. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
21. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005; 112: 2735-52.
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
23. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study. Atherosclerosis 2007; 191: 391-6.
24. Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: findings from the national health and nutrition examination survey III. J Am Coll Cardiol 2004; 43: 1791-6.